Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on February 12, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 12, 2026 Modalis Therapeutics Corporation [4883.T] TOKYO, Feb 12 (Pulse News Wire) – Modalis Therapeutics Corporation (4883.T) reported progress on its MDL-101 program in its fourth quarter earnings release for the fiscal year ending December 2025. Key highlights included final preparations for an investigational new drug (IND) application aimed at central region regulatory authorities, with plans for proof-of-concept (PoC) clinical trials in 2027-28 and c